Evidence map›Paper›PMID 37965050›Full record

ArticleFrontiers in bioengineering and biotechnology2023

Conceptual risk assessment of mosquito population modification gene-drive systems to control malaria transmission: preliminary hazards list workshops.

Ana Kormos, George Dimopoulos, Ethan Bier, Gregory C Lanzaro, John M Marshall, Anthony A James

Open access · goldAbstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Response to "Field Trials Need Genetic Localization, Not Geographic Isolation".The American journal of tropical medicine and hygiene · 2025
    Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Ana KormosVector Genetics Laboratory, University of California, Davis, Davis, CA, United States.
George DimopoulosW. Harry Feinstone Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Malaria Research Institute, Johns Hopkins University, Baltimore, MD, United States.
Ethan BierDepartment of Cell and Developmental Biology, University of California, San Diego, San Diego, CA, United States.
Gregory C LanzaroVector Genetics Laboratory, University of California, Davis, Davis, CA, United States.
John M MarshallDivisions of Epidemiology and Biostatistics, School of Public Health, University of California, Berkeley, Berkeley, CA, United States.
Anthony A JamesDepartments of Microbiology and Molecular Genetics and Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA, United States.
University of California, Davis · USJohns Hopkins University · USUniversity of California, Berkeley · USUniversity of California, Irvine · USUniversity of California, San Diego · US

Funding

Mosquito SAMSP1 and SAMSP2 influence the initial stage of Plasmodium infection of miceR01AI158615 · NIAID · YALE UNIVERSITY · PI DIMOPOULOS, GEORGE, FIKRIG, EROL · 2021 to 2025
$4.1M
Impact of gene-drive systems for population modification on malaria vector mosquitoesR01AI170692 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI DIMOPOULOS, GEORGE, JAMES, ANTHONY A. · 2023 to 2025
$3.2M
The mutagenic chain reaction: a method for autocatalyic gene disseminationR01GM117321 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BIER, ETHAN · 2016 to 2024
$2.5M
Development of next-generation gene drive technologies for Anopheles population engineeringR01AI162911 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BIER, ETHAN · 2021 to 2025
$2.3M
Complete Plasmodium falciparum infection cycle modelR21AI168873 · NIAID · JOHNS HOPKINS UNIVERSITY · PI DIMOPOULOS, GEORGE · 2023 to 2024
$450k
NIAID NIH HHS R01 AI158615NIAID NIH HHS R01 AI162911NIAID NIH HHS R01 AI170692NIAID NIH HHS R21 AI168873NIGMS NIH HHS R01 GM117321
6 · The paper itself

Abstract

The field-testing and eventual adoption of genetically-engineered mosquitoes (GEMs) to control vector-borne pathogen transmission will require them meeting safety criteria specified by regulatory authorities in regions where the technology is being considered for use and other locales that might be impacted. Preliminary risk considerations by researchers and developers may be useful for planning the baseline data collection and field research used to address the anticipated safety concerns. Part of this process is to identify potential hazards (defined as the inherent ability of an entity to cause harm) and their harms, and then chart the pathways to harm and evaluate their probability as part of a risk assessment. The University of California Malaria Initiative (UCMI) participated in a series of workshops held to identify potential hazards specific to mosquito population modification strains carrying gene-drive systems coupled to anti-parasite effector genes and their use in a hypothetical island field trial. The hazards identified were placed within the broader context of previous efforts discussed in the scientific literature. Five risk areas were considered i) pathogens, infections and diseases, and the impacts of GEMs on human and animal health, ii) invasiveness and persistence of GEMs, and interactions of GEMs with target organisms, iii) interactions of GEMs with non-target organisms including horizontal gene transfer, iv) impacts of techniques used for the management of GEMs and v) evolutionary and stability considerations. A preliminary hazards list (PHL) was developed and is made available here. This PHL is useful for internal project risk evaluation and is available to regulators at prospective field sites. UCMI project scientists affirm that the subsequent processes associated with the comprehensive risk assessment for the application of this technology should be driven by the stakeholders at the proposed field site and areas that could be affected by this intervention strategy.

Indexed as

evolution/stabilityGEMSgene-drivegenetic engineeringhuman/animal healthinvasiveness/persistencetarget/nontarget organismstarget product profile (TPP)

Identifiers

PMID37965050
PMCPMC10641379
OpenAlexW4387974901

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.